The efficacy of cyclic and prolonged cyclic regimens of dydrogesterone for recurrence prevention of abnormal uterine bleeding in the reproductive period
V.F.Snegirev Archives of Obstetrics and Gynecology · 13.05.2026 · 13 (2) · 185-193
DOI: 10.17816/aog703511 ↗Kurz gefasst
Fachartikel in der Zeitschrift V.F.Snegirev Archives of Obstetrics and Gynecology, online erschienen am 13.05.2026. Verfasst von Lyudmila A. Ozolinya und 6 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Abnormal uterine bleeding is common during the reproductive period, and despite treatment, recurrences associated with ovulatory dysfunction are frequent, carrying a high risk of infertility and endometrial hyperplasia AIM: To compare the efficacy of different cyclic dydrogesterone regimens for preventing recurrence of abnormal uterine bleeding caused by ovulatory dysfunction during the reproductive period. METHODS: We examined 93 patients aged 27–44 years with abnormal uterine bleeding associated with ovulatory dysfunction. After histological confirmation of endometrial proliferation in biopsy specimens, the patients received dydrogesterone therapy for 6 months. Three groups were formed: group 1 (32 patients planning pregnancy) received dydrogesterone 20 mg/day from day 16 to day 25 of the menstrual cycle; group 2 (31 patients not seeking pregnancy) received dydrogesterone 20 mg/day from day 5 to day 25; group 3 (30 patients who wished to conceive soon)** received dydrogesterone 20 mg/day from day 11 to day 25. Three months after treatment, menstrual cycle pattern and pelvic ultrasound findings were assessed. Statistical analysis was performed using IBM SPSS Statistics 23.0.0.0 (p 0.05). RESULTS: Three months after dydrogesterone therapy, menstrual irregularities with endometrial thickness (M-echo) 7 mm on days 5–7 of the cycle were found in 12 (37.5%) patients in group 1, in 2 (6.4%) in group 2, and in 2 (6.6%) in group 3. CONCLUSION: The prolonged cyclic regimen (days 5–25) and the cyclic regimen (days 11–25) showed statistically significant superiority in efficacy for abnormal uterine bleeding due to ovulatory dysfunction compared with the days 16–25 regimen.
Zitieren
APA
Ozolinya, L. A., Argun, M. Z., Overko, A. V., Khlynova, S. A., Savchenko, T. N., Nasyrova, N. I., & Demchenko, E. V. (2026). The efficacy of cyclic and prolonged cyclic regimens of dydrogesterone for recurrence prevention of abnormal uterine bleeding in the reproductive period. V.F.Snegirev Archives of Obstetrics and Gynecology, 13(2), 185-193. https://doi.org/10.17816/aog703511
Vancouver
Ozolinya LA, Argun MZ, Overko AV, Khlynova SA, Savchenko TN, Nasyrova NI, et al. The efficacy of cyclic and prolonged cyclic regimens of dydrogesterone for recurrence prevention of abnormal uterine bleeding in the reproductive period. V.F.Snegirev Archives of Obstetrics and Gynecology. 2026;13(2):185-193. doi:10.17816/aog703511
BibTeX
@article{Ozolinya2026,
author = {Ozolinya, Lyudmila A. and Argun, Madina Z. and Overko, Alexey V. and Khlynova, Svetlana A. and Savchenko, Tatyana N. and Nasyrova, Nailya I. and Demchenko, Elizaveta V.},
title = {The efficacy of cyclic and prolonged cyclic regimens of dydrogesterone for recurrence prevention of abnormal uterine bleeding in the reproductive period},
journal = {V.F.Snegirev Archives of Obstetrics and Gynecology},
year = {2026},
volume = {13},
number = {2},
pages = {185--193},
doi = {10.17816/aog703511}
}
EUVIMED